Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
British Journal of Haematology|April 17, 2007
Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescueL Nolan, P Lorigan, S Chilton, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 28, 2003
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanomaS Danson, P Lorigan, A Arance, et al.
European Journal of Cancer (Oxford, England : 1990)|June 30, 2012
Treatment patterns and outcomes among patients diagnosed with unresectable stage III or IV melanoma in Europe: a retrospective, longitudinal survey (MELODY study)C Lebbe, P Lorigan, P Ascierto, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|October 11, 2007
A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centreA Molassiotis, M P Saunders, J Valle, et al.
Cancer|August 16, 2001
Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinomaS C White, P Lorigan, M R Middleton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 11, 2006
A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1)R Booton, P Lorigan, H Anderson, et al.
European Journal of Cancer (Oxford, England : 1990)|April 7, 2012
Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study)K Johnston, A R Levy, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 14, 2009
The strength of female sex as a prognostic factor in small-cell lung cancer: a pooled analysis of chemotherapy trials from the Manchester Lung Group and Medical Research Council Clinical Trials UnitP Wheatley-Price, C Ma, L F Ashcroft, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 8, 2017
Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanomaR J Lee, G Gremel, A Marshall, et al.
The British Journal of Dermatology|July 17, 2013
Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY studyP Lorigan, M Marples, M Harries, et al.
Pageof 7